Array Biopharma, Inc. (ARRY) Misses Q3 EPS by 4c; to Commence MEK162 Phase 3

May 6, 2013 4:13 PM

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q3 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15). Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found